文献速递产科

真空辅助止血装置与子宫球囊填塞治疗难治性宫缩乏力性产后出血:一项方案驱动诊疗路径下的回顾性队列研究

Vacuum‐assisted hemorrhage control device versus uterine balloon tamponade for refractory atonic postpartum hemorrhage in a protocol‐driven care pathway—A retrospective cohort study
RSS 订阅 · Acta Obstetricia et Gynecologica Scandinavica · 2026-10-26

在新加坡国立大学医院开展的回顾性队列研究中,53例难治性宫缩乏力性产后出血患者分别接受真空辅助止血装置(VHD,20例)或子宫球囊填塞(UBT,33例)治疗,诊疗均遵循E-MOTIVE与ROTEM指导的输血方案。VHD组复合不良结局发生率低于UBT组(45.0%对75.8%,未校正OR 0.26,95%CI 0.08–0.86,p=0.03),但校正前置胎盘与剖宫产分娩后差异不再有统计学意义(校正OR 0.38,95%CI 0.10–1.41,p=0.15)。

要点

  • VHD组复合不良结局45.0%,UBT组75.8%,未校正OR 0.26(95%CI 0.08–0.86,p=0.03)。
  • 校正前置胎盘与剖宫产分娩后,复合结局差异不再有统计学意义(校正OR 0.38,95%CI 0.10–1.41,p=0.15)。
  • VHD组红细胞悬液输注中位数1单位,UBT组2单位(p=0.009)。

核心结论

  • 在难治性宫缩乏力性产后出血中,VHD的结局与球囊填塞相当,且输血需求更低、住院时间更短。
  • VHD可能成为包含E-MOTIVE组合与ROTEM指导输血的标准化产后出血方案的组成部分,值得在更广泛临床环境中进一步评估。

研究设计与样本

  • 新加坡国立大学医院开展的回顾性队列研究,纳入2020年1月至2025年9月期间因原发性产后出血接受UBT或VHD治疗的全部女性。
  • 共53例符合纳入标准,其中UBT组33例、VHD组20例,期间实施ROTEM指导输血与E-MOTIVE对齐的实践。

主要发现

  • 复合不良结局VHD组45.0%对UBT组75.8%(未校正OR 0.26,95%CI 0.08–0.86,p=0.03),校正后OR 0.38(95%CI 0.10–1.41,p=0.15)。
  • UBT组前置胎盘(45.5%对5.0%)与剖宫产分娩(78.8%对50.0%)比例更高,置入装置时估计失血量中位数两组相当(1500 mL)。
  • 红细胞悬液输注中位数VHD组1单位对UBT组2单位(p=0.009),接受≥4单位者5.0%对36.4%(p=0.02),血浆输注5.0%对36.4%(p=0.02)。
  • 装置留置时间VHD组10.1小时对UBT组24.3小时(p<0.001),住院时间54小时对72小时(p=0.007),高依赖病房入住45.0%对72.7%(p=0.04)。

关键数值与推荐

  • 原文未报告指南或共识推荐条款。

临床怎么用

  • 作者认为VHD可能成为包含E-MOTIVE组合与ROTEM指导输血的标准化产后出血方案的组成部分,并建议在更广泛临床环境中进一步评估。

局限性

  • 原文为回顾性队列研究,共53例(UBT组33例、VHD组20例),样本量有限。
  • 校正前置胎盘与剖宫产分娩后复合结局差异不再有统计学意义(校正OR 0.38,95%CI 0.10–1.41,p=0.15),置信区间较宽。
  • 作者指出VHD值得在更广泛临床环境中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this retrospective cohort study, the vacuum-assisted hemorrhage-control device for refractory postpartum hemorrhage, implemented within an E-MOTIVE and ROTEM-guided protocol, was associated with reduced transfusion requirements, decreased device indwelling time, fewer high-dependency admissions, and a shorter duration of hospital stay compared to uterine balloon tamponade. Abstract Introduction Globally, 1 in 5 maternal deaths are attributable to major postpartum hemorrhage (PPH), despite widespread uterotonic use. Intrauterine tamponade is recommended as second-line therapy for refractory atonic PPH. Uterine balloon tamponade (UBT) achieves hemostasis through intrauterine pressure. Conversely, the vacuum-assisted hemorrhage-control device (VHD) promotes uterine contraction through negative pressure. Limited data compare these modalities. We compared the clinical effectiveness of UBT and VHD in refractory atonic PPH. Material and Methods This retrospective cohort study was conducted at the National University Hospital in Singapore and included all women treated for primary PPH with either the UBT or VHD between January 2020 and September 2025, during which ROTEM-guided transfusion and E-MOTIVE-aligned practices were implemented. The composite morbidity endpoint, comprising transfusion of ≥4 units of packed red blood cells (PRBC), plasma or cryoprecipitate administration, examination under anesthesia, high dependency or intensive care unit admission, or device failure was compared between groups with logistic regression adjusted for placenta previa major and cesarean delivery. Results Fifty-three women met inclusion criteria (33 UBT, 20 VHD). The composite morbidity outcome occurred less frequently with VHD than UBT (45.0% versus 75.8%; unadjusted OR 0.26, 95% CI 0.08–0.86, p = 0.03); after adjusting for placenta previa major and cesarean delivery, this difference was no longer statistically significant (adjusted OR 0.38, 95% CI 0.10–1.41, p = 0.15). Baseline characteristics were similar except for higher rates of placenta previa (45.5% versus 5.0%) and cesarean delivery (78.8% versus 50.0%) in the UBT group. Median estimated blood loss at device insertion was comparable (1500 mL). Among secondary outcomes, VHD was associated with lower median PRBC transfusion (1 vs. 2 units, p = 0.009), fewer women receiving ≥4 PRBC units (5.0% versus 36.4%, p = 0.02), fewer plasma transfusions (5.0% versus 36.4%, p = 0.02), shorter device indwelling duration (10.1 versus 24.3 h, p < 0.001), shorter hospital stay (54 versus 72 h, p = 0.007), and fewer high-dependency admissions (45.0% versus 72.7%, p = 0.04). Conclusions The VHD demonstrated outcomes comparable to balloon tamponade in managing refractory atonic PPH, with lower transfusion requirements and shorter hospitalization. VHD may be a useful component of standardized PPH protocols incorporating the E-MOTIVE bundle and ROTEM-guided transfusion, warranting further evaluation in broader clinical settings.

来源:Acta Obstetricia et Gynecologica Scandinavica,查看原文。版权归原作者所有。

引用

  1. Acta Obstetricia et Gynecologica Scandinavica:Vacuum‐assisted hemorrhage control device versus uterine balloon tamponade for refractory atonic postpartum hemorrhage in a protocol‐driven care pathway—A retrospective cohort study

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。